Multiple Myeloma Clinical Trial

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Summary

This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide with and without dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

All participants must have a documented diagnosis of relapse/refractory Multiple Myeloma and have measurable disease as defined per IMWG criteria.
All participants must have received at least 3 prior lines of MM therapy with IMiD, PI and Anti-CD-38, and progressed on their last therapy (prior BCMA targeted therapy allowed).
All participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0,1or 2.
All participants must have adequate organ function.
Females of childbearing potential (FCBP) or male participant must agree to follow contraception requirements.

Exclusion Criteria:

All participants with non-secretory MM
All participants with known auto-immune disease
All participants with history of life-threatening toxicity related to prior immune therapy.
All participants with active graft versus host disease after allogeneic stem cell transplantation.
All participants with active, unstable cardiovascular function.
All participants with active infection requiring systemic therapy.
All participants with hypersensitivity to any of the treatments.
All participants with any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment.

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

16

Study ID:

NCT05289492

Recruitment Status:

Terminated

Sponsor:

iTeos Belgium SA

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 13 Locations for this study

See Locations Near You

Banner MD Anderson
Gilbert Arizona, 85234, United States
Eastern Connecticut Hematology & Oncology
Norwich Connecticut, 06360, United States
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States
Fred Hutchinson Cancer Center
Seattle Washington, 98109, United States
ZNA Cadix
Antwerp , 2020, Belgium
Institut Jules Bordet
Brussels , 1070, Belgium
Universitaire Ziekenhuizen KU Leuven
Leuven , 3000, Belgium
CHU Amiens
Amiens , 80054, France
Centre Hospitalier Universitaire de Nantes
Nantes , 44093, France
APHP Hôpital Saint-Antoine
Paris , 75012, France
CHU de Poitiers
Poitiers , 86021, France
CHU Toulouse
Toulouse , 31059, France
Hospital Fundacion Jimenez Diaz
Madrid , 28040, Spain

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

16

Study ID:

NCT05289492

Recruitment Status:

Terminated

Sponsor:


iTeos Belgium SA

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.